We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Appeals Court Puts Brakes on Launch of Neupogen Biosimilar
Appeals Court Puts Brakes on Launch of Neupogen Biosimilar
A federal appeals court has granted a temporary injunction barring Sandoz from marketing its biosimilar of Amgen’s blockbuster chemotherapy drug Neupogen.